Thiazolidinedione (TZD) compounds are a new class of insulin-sensitizing drugs used in the treatment of type II diabetes. TZDs are high affinity ligands of peroxisome proliferator activated receptor-gamma (PPARg); a member of the nuclear receptor family that controls the expression of genes in the target tissues of insulin action. Thus, also involved in the control of various aspects of lipid metabolism. Development of hyperlipidemia, by using a hyperlipidemic diet given to animal model, are important for studying new chemical or natural products with hypolipidemic potential. In the current study were evaluated the metabolic effects of new (TZD) derivative: 3-(4-methyl-benzyl)-5-(2,4 -dimethoxy-benzilidene)-thiazolidine-2,4-dione (GQ6) in mice with hypercholesterolemia and hypertriglyceridemia. Hyperlipidemia was developed in groups of 6 animals by feeding dehydrated oxen brain (40%) plus essential nutrients, for 75 days. Then, the animals were trated for 16 days with the new compound GQ6 (10mg/Kg/day), and the control group with vehicle (CMC), all the groups continued to receive the diet. To validate the experimental model, a hyperlipidemic group treated with Rosiglitazone, a commercial thiazolidinedione, was adopted. The serum triglyceride, total cholesterol and serum glucose level were analyzed. Our results showed significant decrease (p<0.01) by 38% in glucose levels, 32% in triglyceride levels and 38% in total cholesterol levels from hyperlipidemic mice treated with GQ6, when comparing data before and after teatment. There was also significant decrease (p<0.01) in total cholesterol levels by 50% in this group, in comparasion to the hyperlipidemic control mice. The current studies show that new (TZD) derivative GQ6 is able to reduce glucose, triglyceride and total cholesterol levels in hyperlipidemic mice. These results indicate that GQ6 was able to improve glycemic control and prevent cardiovascular risk factors. Furthermore, comprehensive studies are required to reveal the mechanism action of GQ6.